Bank of America’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-87,846
| Closed | -$8.96M | – | 8060 |
|
|
2023
Q2 | $8.96M | Sell |
87,846
-133,850
| -60% | -$12.7M | ﹤0.01% | 2810 |
|
|
2023
Q1 | $20.2M | Buy |
221,696
+18,685
| +9% | +$1.1M | ﹤0.01% | 2114 |
|
|
2022
Q4 | $7.71M | Buy |
203,011
+32,475
| +19% | +$1.12M | ﹤0.01% | 2943 |
|
|
2022
Q3 | $4.29M | Buy |
170,536
+81,795
| +92% | +$2.27M | ﹤0.01% | 3491 |
|
|
2022
Q2 | $2.7M | Buy |
88,741
+10,609
| +14% | +$317K | ﹤0.01% | 4033 |
|
|
2022
Q1 | $2.56M | Sell |
78,132
-17,086
| -18% | -$507K | ﹤0.01% | 4348 |
|
|
2021
Q4 | $2.51M | Buy |
95,218
+6,607
| +7% | +$511K | ﹤0.01% | 4330 |
|
|
2021
Q3 | $8.91M | Buy |
88,611
+29,158
| +49% | +$3.42M | ﹤0.01% | 2976 |
|
|
2021
Q2 | $8.41M | Sell |
59,453
-22,776
| -28% | -$2.57M | ﹤0.01% | 3008 |
|
|
2021
Q1 | $8.2M | Buy |
82,229
+16,971
| +26% | +$1.98M | ﹤0.01% | 2917 |
|
|
2020
Q4 | $8.07M | Buy |
65,258
+3,905
| +6% | +$513K | ﹤0.01% | 2702 |
|
|
2020
Q3 | $5.98M | Sell |
61,353
-2,699
| -4% | -$337K | ﹤0.01% | 2744 |
|
|
2020
Q2 | $9.99M | Sell |
64,052
-31,080
| -33% | -$4.72M | ﹤0.01% | 2211 |
|
|
2020
Q1 | $13.7M | Buy |
95,132
+3,366
| +4% | +$650K | ﹤0.01% | 1796 |
|
|
2019
Q4 | $18.8M | Buy |
91,766
+3,212
| +4% | +$586K | ﹤0.01% | 1940 |
|
|
2019
Q3 | $7.11M | Buy |
88,554
+25,280
| +40% | +$2.15M | ﹤0.01% | 2850 |
|
|
2019
Q2 | $5.97M | Sell |
63,274
-2,144
| -3% | -$185K | ﹤0.01% | 3057 |
|
|
2019
Q1 | $5.59M | Sell |
65,418
-9,014
| -12% | -$748K | ﹤0.01% | 3056 |
|
|
2018
Q4 | $4.17M | Buy |
74,432
+64,454
| +646% | +$3.94M | ﹤0.01% | 3180 |
|
|
2018
Q3 | $816K | Buy |
9,978
+4,244
| +74% | +$299K | ﹤0.01% | 4618 |
|
|
2018
Q2 | $200K | Sell |
5,734
-602
| -10% | -$18.3K | ﹤0.01% | 5410 |
|
|
2018
Q1 | $129K | Buy |
6,336
+1,958
| +45% | +$50.4K | ﹤0.01% | 5607 |
|
|
2017
Q4 | $124K | Buy |
4,378
+2,613
| +148% | +$72.9K | ﹤0.01% | 5651 |
|
|
2017
Q3 | $55K | Buy |
1,765
+750
| +74% | +$22.6K | ﹤0.01% | 5902 |
|
|
2017
Q2 | $32K | Sell |
1,015
-112
| -10% | -$2.75K | ﹤0.01% | 6060 |
|
|
2017
Q1 | $26K | Buy |
1,127
+345
| +44% | +$8.52K | ﹤0.01% | 6209 |
|
|
2016
Q4 | $17K | Buy |
782
+545
| +230% | +$13.8K | ﹤0.01% | 6406 |
|
|
2016
Q3 | $6K | Sell |
237
-16,300
| -99% | -$323K | ﹤0.01% | 6563 |
|
|
2016
Q2 | $327K | Buy |
+16,537
| New | +$321K | ﹤0.01% | 4942 |
|
Other funds holding RETA
Bank of America's RETA Position: Q3 2023 in Review
Bank of America sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 87,846 shares — an estimated $8.96M sold.
Bank of America first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $20.2M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Bank of America reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Bank of America sold 87,846 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.96M.
- Bank of America first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Bank of America's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $20.2M in Q1 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.